1. At a Glance
Tarsons Products Ltd — India’s homegrown labware manufacturer that once made test tubes for others’ experiments — is now conducting a survival experiment of its own. The company’s Q2 FY26 report looks like a chemistry reaction gone slightly wrong: Revenue ₹102 crore (up 3% YoY) but PAT ₹3.3 crore (down 67.7%). The stock, which once touched ₹465, now trades around ₹240, proving that volatility isn’t limited to Bunsen burners.
With a market cap of ₹1,275 crore and a P/E of 62x, the company’s valuation still thinks it’s making biotech breakthroughs. Yet, ROE of 4.75% and ROCE of 6.9% tell us the beaker’s only half full. Debt has ballooned to ₹396 crore, and even the scientists in their labs must be wondering — “Where did all that capex money go?”
But here’s the silver lining: five plants (and two upcoming), a strong product portfolio of 1,700+ SKUs, and 45 global distributors in 40 countries. Tarsons is India’s pipette prince with a global accent.
As the Bible says, “Let there be light.” And Tarsons is certainly working on it — preferably through a microscope.
2. Introduction
Imagine an Indian company that quietly makes the plastic gear every scientist touches — pipettes, centrifuge tubes, bottles, beakers — and yet, nobody outside a lab knows its name. That’s Tarsons for you: the company that literally holds India’s biotech dreams in its petri dishes.
Started when “labware” was still a foreign word, Tarsons turned into a market leader by making “Made in India” lab consumables cool before “Make in India” was even a slogan. Today, it supplies to pharma biggies like Sun Pharma, Lupin, HUL, and Mankind, and exports to 40+ countries.
But FY25–26 hasn’t been all sterile and safe. Rising depreciation (₹80 crore), heavy capex for two new plants, and a German acquisition (Nerbe GmbH) have diluted margins like a poorly mixed reagent. Still, Tarsons remains one of the few Indian firms in a high-barrier industry where competition is as tough as autoclavable polypropylene.
So, what’s cooking in the beakers? Let’s find out.
3. Business Model – WTF Do They Even Do?
Tarsons makes the labware that makes the science possible. Think of them as the invisible backbone of pharma R&D and diagnostics. They’re not discovering vaccines; they’re making the vials you keep them in.
Their products are divided into three main segments:
- Consumables (55%) – Pipette tips, petri dishes, cryovials, centrifuge tubes — the once-and-throw heroes of every lab.
- Reusables (40%) – Bottles, beakers, carboys, measuring cylinders — reusable, autoclavable, and occasionally unbreakable.
- Others (5%) – Benchtop equipment like mini centrifuges, pipettors, and vortex shakers that keep labs whirring.
In FY24, 70% of revenue came from India (thanks to pharma and research institutes), and 30% from exports. But here’s the twist — 65% of their exports are ODM (Original Design Manufacturing) for
